Viewing nowBonjenic Tablet 150 mg (Ibandronate Sodium Hydrate)
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.

MFDS item code 201205931 · Approved 2012.06.26 · Insurance code 645403680
Treatment of osteoporosis in postmenopausal women
This medication is used to treat osteoporosis, which commonly occurs in postmenopausal women. Osteoporosis is a condition characterized by decreased bone density, increasing the risk of fractures. This medication strengthens bones and increases bone density, thereby reducing the risk of fractures. It helps improve symptoms of postmenopausal osteoporosis and maintain bone health.
Take 1 tablet once monthly, regularly on the same day each month in the morning, with plenty of water at least 1 hour before consuming food, beverages (other than water), or other oral medications or dietary supplements (including calcium): - This medicine should be swallowed with plenty of water (180-240ml) while standing or sitting upright, and you must not lie down for 60 minutes after taking it. - Mineral water may reduce the absorption of this medicine, so take it with plain water. - To avoid esophageal ulcers, do not chew or suck the tablet. If a patient forgets to take a dose on the regularly scheduled day: - If 8 days or more remain until the next regularly scheduled dose, take 1 tablet the morning after realizing that the dose was missed, and thereafter take 1 tablet each month on the originally scheduled day. - If 7 days or fewer remain until the next regularly scheduled dose, take 1 tablet on the next regularly scheduled day, and thereafter take 1 tablet each month on the originally scheduled day. - Do not take 2 tablets in the same week. Patients with inadequate dietary intake should supplement with calcium or vitamin D. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary for patients with mild or moderate renal impairment with creatinine clearance of 30mL/min or higher. Use of this medicine is not recommended for patients with creatinine clearance below 30mL/min because clinical experience is insufficient. Older adults No dosage adjustment is necessary.
Efficacy and safety in children 18 years of age or younger have not been studied.
This medication should not be used in certain patients. For example, individuals who are allergic to this medication or its components, those with untreated hypocalcemia, those unable to sit upright or stand for more than 60 minutes, individuals with esophageal dysfunction where food does not pass easily, and those with genetic issues such as lactose intolerance or galactose intolerance should not take this medication. Caution should be exercised in patients with severe renal failure. Individuals with significantly impaired kidney function require particular attention. Some patients may experience various side effects including dyspepsia, nausea, abdominal pain, diarrhea, headache, muscle pain, joint pain, and rash while taking this medication. Most side effects are mild to moderate and may not require discontinuation of treatment. Moreover, this medication can irritate the esophagus and may cause difficulty swallowing, esophagitis, or esophageal ulcers; therefore, it is important to remain upright for at least 60 minutes after taking the medication and strictly adhere to the administration guidelines. As a bisphosphonate, there is a rare risk of osteonecrosis of the jaw, inflammation of the eyes, and severe allergic reactions; thus, patients should consult a physician immediately if any unusual symptoms occur. This medication may have reduced absorption when taken with food, milk, calcium supplements, or antacids; therefore, patients should refrain from consuming other foods or medications for at least 1 hour after taking this medication. Pregnant or nursing women are advised to avoid using this medication as its safety has not been established. Elderly patients do not require special dose adjustment; however, safety and efficacy have not been confirmed in children under 18 years of age, so it is not used in this population. In case of overdose, gastrointestinal disturbances or hypocalcemia may occur, so it is crucial to adhere strictly to the prescribed dosage; immediate medical attention is required if any problems arise. Lastly, this medication should be stored out of the reach of children, and unused medications should be disposed of properly to prevent environmental contamination.
dyspepsia, nausea, abdominal pain, diarrhea, bloating, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, gastritis, esophagitis, muscle cramp, musculoskeletal pain, musculoskeletal stiffness, dysphagia, vomiting, esophageal ulcer, esophageal stricture, dizziness, low back pain, duodenitis, hypersensitivity reaction, angioedema, facial swelling, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external auditory canal, anaphylactic reaction, shock, allergic reaction, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical subtrochanteric and femoral neck fractures, atypical fractures of the ilium, abnormal sensations in the eyes, weakness, pruritus
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly closed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to preserve the medication's effectiveness.
White to almost white rectangular film-coated tablets
1 tablet (1 tablet/PTP x 1)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowIbandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.